ALLO-501/501A
Relapsed/Refractory Non-Hodgkin Lymphoma
Phase 1Completed/Data Presented
Key Facts
Indication
Relapsed/Refractory Non-Hodgkin Lymphoma
Phase
Phase 1
Status
Completed/Data Presented
Company
About Allogene Therapeutics
Allogene Therapeutics is dedicated to creating and leading the next revolution in cell therapy by delivering the first allogeneic CAR T cell products. The company leverages its proprietary AlloCAR T platform, featuring multiplex gene-engineering, gene-editing, and a proprietary lymphodepletion regimen, to develop scalable, on-demand treatments. With a pipeline targeting blood cancers, solid tumors like renal cell carcinoma, and autoimmune diseases, Allogene is advancing multiple clinical programs, including the industry's first pivotal Phase 2 trial for a frontline allogeneic CAR T in lymphoma. The company is publicly traded and led by a team with deep CAR T expertise.
View full company profileTherapeutic Areas
Other Relapsed/Refractory Non-Hodgkin Lymphoma Drugs
| Drug | Company | Phase |
|---|---|---|
| ANKTIVA® + CD19 t-haNK | ImmunityBio | Phase 1 |